Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: Role of drug induced homocysteinemia?

Thrombosis Research

Volumn 122, Issue 3, 2008, Pages 314-319

  Lacut, Karine ^a,b   Le Gal, Grégoire ^a,b   Abalain, Jean Hervé ^b   Mottier, Dominique ^a,b   Oger, Emmanuel ^a,b  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Case control study; Fibrates; Homocysteine; Statins; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; CASE-CONTROL STUDIES; CLOFIBRIC ACID; DATABASES, FACTUAL; FEMALE; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 45849103152     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.10.014     Document Type: Article

References (20)

1. Grady D., et al., for the Heart and Estrogen/progestin Replacement Study research group. Postmenopausal hormone replacement therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 132 (2000) 689-696
2. Herrington D.M., Vittinghoff E., Lin F., Fong J., Harris F., Hunninghake D., et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 105 (2002) 2962-2967
3. Ray J.G., Mamdani M., Tsuyuki R.T., Anderson D.R., Yeo E.L., and Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 161 (2001) 1405-1410
4. Lacut K., Oger E., Le Gal G., Couturaud F., Louis S., Leroyer C., et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospitalised-based case-control study. Fundam Clin Pharmacol 18 (2004) 477-482
5. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
6. den Heijer M., Lewington S., and Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 3 (2005) 292-299
7. De Lorgeril M., Salen P., Paillard F., Lacan P., and Richard G. Lipid-lowering drugs and homocysteine. Lancet 353 (1999) 209-210
8. Dierkes J., Westphal S., and Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 354 (1999) 219-220
9. Giral P., Bruckert E., Jacob N., Chapman M.J., Foglietti M.J., and Turpin G. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 154 (2001) 421-427
10. Sebestjen M., Keber I., Zegura B., Simcic S., Bozic M., Migaud Fressart M., et al. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost 92 (2004) 1129-1135
11. Milionis H.J., Papakostas J., Kakafika A., Chasiotis G., Seferiadis K., and Elisaf M.S. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 43 (2003) 825-830
12. Oger E., et al., for the EDITH (Etude des Déterminants/Interaction de la THrombose veineuse) Collaborative Study Group. Interrelation of hyperhomocysteinemia and inherited risk factors for venous thromboembolism. Results from the E.D.I.TH. study: A hospital-based case-control study. Thromb Res 120 (2007) 207-214
13. Rosenson R.S., and Tangney C.C. Anti-atherothrombotic properties of statins. Implication for cardiovascular event reduction. JAMA 279 (1998) 1643-1650
14. Farmer J.A. Pleiotropic effects of statins. Curr Atheroscl Rep 2 (2000) 208-217
15. Dangas G., Smith D.A., Badimon J.J., Unger A.H., Shao J.H., Meraj P., et al. Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin. Am J Cardiol 84 (1999) 639-643
16. Szczeklik A., Musial J., Undas A., Gajewski P., Gora P., Swadzba J., et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of ASA in patients with marked hypercholesterolemia. J Am Coll Cardiol 33 (1999) 1286-1293
17. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
18. Oger E., et al., for the EDITH Collaborative Study Group. Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case-control study. J Thromb Haemost 4 (2006) 793-799
19. Ageno W., Prandoni P., Romualdi E., Ghirarduzzi A., Dentali F., Pesavento R., et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 4 (2006) 1914-1918
20. Ay C., Tengler T., Vormittag R., Simanek R., Dorda W., Vukovich T., et al. Venous thromboembolism-a manifestation of the metabolic syndrome. Haematologica 92 (2007) 374-380